How would you treat a case of mixed histology NSCLC/SCLC that rapidly progresses following chemoradiation and durvalumab?  

In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alternative makes more sense? 



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice